191 related articles for article (PubMed ID: 15356792)
1. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.
Imhof A; Balajee SA; Fredricks DN; Englund JA; Marr KA
Clin Infect Dis; 2004 Sep; 39(5):743-6. PubMed ID: 15356792
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
Trifilio S; Singhal S; Williams S; Frankfurt O; Gordon L; Evens A; Winter J; Tallman M; Pi J; Mehta J
Bone Marrow Transplant; 2007 Sep; 40(5):451-6. PubMed ID: 17589527
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
5. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
Siwek GT; Dodgson KJ; de Magalhaes-Silverman M; Bartelt LA; Kilborn SB; Hoth PL; Diekema DJ; Pfaller MA
Clin Infect Dis; 2004 Aug; 39(4):584-7. PubMed ID: 15356827
[TBL] [Abstract][Full Text] [Related]
6. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.
Cordonnier C; Maury S; Pautas C; Bastié JN; Chehata S; Castaigne S; Kuentz M; Bretagne S; Ribaud P
Bone Marrow Transplant; 2004 May; 33(9):943-8. PubMed ID: 15034546
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient.
Tong SY; Peleg AY; Yoong J; Handke R; Szer J; Slavin M
Transpl Infect Dis; 2007 Sep; 9(3):241-3. PubMed ID: 17605752
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.
Marty FM; Cosimi LA; Baden LR
N Engl J Med; 2004 Feb; 350(9):950-2. PubMed ID: 14985500
[No Abstract] [Full Text] [Related]
9. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.
Lamaris GA; Ben-Ami R; Lewis RE; Chamilos G; Samonis G; Kontoyiannis DP
J Infect Dis; 2009 May; 199(9):1399-406. PubMed ID: 19358672
[TBL] [Abstract][Full Text] [Related]
10. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
[TBL] [Abstract][Full Text] [Related]
11. Emergence of Candida albicans fungemia during voriconazole therapy.
Mohammedi I; Thiebaut A; Piens MA; Argaud L; Martin O; Robert D
J Infect; 2005 Oct; 51(3):e83-4. PubMed ID: 16230209
[No Abstract] [Full Text] [Related]
12. Candida glabrata fungemia: experience in a tertiary care center.
Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
[TBL] [Abstract][Full Text] [Related]
13. [Experience with voriconazole in invasive aspergillosis].
Thiel E; Schwartz S
Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
[TBL] [Abstract][Full Text] [Related]
14. Breakthrough invasive pulmonary aspergillosis despite empirical voriconazole therapy for febrile neutropenia: case report and review of the literature.
Meyer M; Waldvogel S; Chalandon Y; Bongiovanni M; Pache JC; Van Delden C
Scand J Infect Dis; 2007; 39(8):731-3. PubMed ID: 17654353
[TBL] [Abstract][Full Text] [Related]
15. First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation.
Auberger J; Lass-Flörl C; Clausen J; Bellmann R; Buzina W; Gastl G; Nachbaur D
Diagn Microbiol Infect Dis; 2008 Nov; 62(3):336-9. PubMed ID: 18687556
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies.
Myoken Y; Kyo T; Sugata T; Murayama SY; Mikami Y
Haematologica; 2006 Feb; 91(2):287-8. PubMed ID: 16461328
[TBL] [Abstract][Full Text] [Related]
17. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
[TBL] [Abstract][Full Text] [Related]
18. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases.
Mathis AS; Shah NK; Friedman GS
Transplant Proc; 2004 Nov; 36(9):2708-9. PubMed ID: 15621130
[TBL] [Abstract][Full Text] [Related]
19. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
20. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
Belazi M; Velegraki A; Koussidou-Eremondi T; Andreadis D; Hini S; Arsenis G; Eliopoulou C; Destouni E; Antoniades D
Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
